menu
    • menu
    [{"orgOrder":0,"company":"Frontier Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Albuvirtide","moa":"HIV-1 fusion","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Frontier Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frontier Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Frontier Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Frontier Biotechnologies","sponsor":"Affiris","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Affitope AT04","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Frontier Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Frontier Biotechnologies \/ Frontier Biotechnologies","highestDevelopmentStatusID":"6","companyTruncated":"Frontier Biotechnologies \/ Frontier Biotechnologies"},{"orgOrder":0,"company":"Frontier Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bofutrelvir","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Frontier Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Frontier Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Frontier Biotechnologies \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Frontier Biotechnologies

    Menu

    Frontier Biotechnologies

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Frontier Biotechnologies

                            China arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Frontier Biotechnologies

                            China arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bofutrelvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Frontier Biotechnologies Announces Positive Phase 1 Results of Its First Coronavirus Main Protease (MPRO) Smal...

                            Details : FB2001 (bofutrelvir) has demonstrated in vivo antiviral activity in the lung and brain tissue of SARS-CoV-2 mouse model without the need for pharmacokinetic boosting.

                            Brand Name : FB2001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 08, 2022

                            Lead Product(s) : Bofutrelvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Frontier Biotechnologies

                            China arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Frontier Biotechnologies

                            China arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Affitope AT04,Aluminium Oxyhydroxide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Recipient : Affiris

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            AFFiRiS and Frontier Biotechnologies Announce License Agreement for AFFITOPE®AT04, an Active Immunotherapy Ta...

                            Details : Subject to the terms of the agreement, Frontier Biotechnologies will be responsible for all development costs for AFFITOPE® AT04 occurring in Greater China and will receive the rights to develop, manufacture and exclusively commercialize AT04 in the lic...

                            Brand Name : Affitope AT04

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 22, 2021

                            Lead Product(s) : Affitope AT04,Aluminium Oxyhydroxide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Recipient : Affiris

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Frontier Biotechnologies

                            China arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Frontier Biotechnologies

                            China arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Albuvirtide,Lopinavir,Ritonavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Second-Line Albuvirtide-Based 2-Drug Regimen Non-Inferior to 3-Drug Standard Therapy: Presented at IAS

                            Details : The results of the randomized controlled, open-labelled, multicenter, non-inferiority study showed successful achievement of the primary endpoint, with a good proportion of patients on the ABT regimen with HIV RNA less than 50 copies/mL at 48 weeks.

                            Brand Name : Aikening

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            July 19, 2021

                            Lead Product(s) : Albuvirtide,Lopinavir,Ritonavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth